Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 27, 2023Alzheimer s Research & TherapyOpen Access

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

Bruno DuboisBruno DuboisBoston UniversityJLJesús López‐ArrietaHospital Universitario La PazSLStanley LipschitzThe Medical Oncology Centre of Rosebank

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dubois et al. (2023) studied this question.

synapsesocial.com/papers/6aa5f3a02e0c4dc4f87f3084https://doi.org/10.1186/s13195-023-01169-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neuroimmune Activation Drives Multiple Brain States2018 · 50 citations
  2. 2Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain2021 · 180 citations
  3. 3Alzheimer’s disease drug-development pipeline: few candidates, frequent failures2014 · 1,794 citations
  4. 4Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer’s Disease and Multiple Sclerosis2019 · 141 citations
  5. 5The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial2007 · 114 citations